🇺🇸 FDA

Company profile · Sponsor

Pasithea

Pasithea Therapeutics

KTTA · NYSE pharma MIAMI BEACH, FL, USA
Pipeline
3
Drugs
0
Patents
0

Quick answer

Pasithea (KTTA) is a pharma company. headquartered in MIAMI BEACH, FL, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker KTTA
Exchange NYSE
Company type pharma
Headquarters MIAMI BEACH, FL, USA
SEC CIK 0001841330

Pipeline (3)

Search pipeline →

  1. A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition

    Pasithea

    Solid Tumors

    phase 1 other active

    1 trial

  2. PAS-004 Capsules

    Pasithea

    RAS Mutation

    phase 1 small molecule active

    1 trial

  3. PAS-004 Tablets

    Pasithea

    NF1 Mutation

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is Pasithea?

Pasithea (KTTA) is a pharma company. headquartered in MIAMI BEACH, FL, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Pasithea sponsor?

We track 3 ClinicalTrials.gov-linked programs for Pasithea, including A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Pasithea company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.